Kyverna therapeutics appoints mert aktar to its board of directors

Enriches board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapy emeryville, calif. , oct. 21, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotechnology executive and cell therapy veteran mert aktar as an independent director to its board of directors.
KYTX Ratings Summary
KYTX Quant Ranking